Bryan Garnier - Bic (BB) BIC Q3 2024 results preview: a continuation of Q2 trends

Report

Bryan Garnier

Cedric Rossi

BIC Q3 2024 results preview: a continuation of Q2 trends

In light of recent publications from US & European retailers, we expect BIC's Q3 numbers to show a continuation of Q2 trends, i.e. subdued LFL growth and resilient margins. The US market (39% of sales) is set to be the weak spot again as the US retailing sector was hit by a wave of lowered sale

03/10/2024 1 EN

Underlying

Bic

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Cedric Rossi

Other Reports on these Companies

Bryan Garnier

On the shelves now: Consumer weekly #42

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we look at the resolution of the ILA port strike which threatened the US holiday sho

4h / 38m 4h / 38m 1 EN

Bryan Garnier

BIC: a mixed bag of H1 2024 numbers but resilient margin trajectories

The LFL sales decline in Q2 (-0.9%) was slightly more pronounced than the CSSe was expecting (-0.6%) but we noted a surprising 90bp-expansion in aEBIT margin to 17.4%, well above expectations (15.1%), supporting BIC's margin guidance for a "slight improvement" over FY24 despite the FY sales outlook

August 1, 2024 August 1, 2024 1 EN

On the shelves now: Consumer weekly #42

4h / 38m 4h / 38m 1 EN

Bruno Bulic

Bruno Bulic

Abivax: Obefazimod in Crohn's disease clinical development

Abivax announced the start of clinical investigations in Crohn’s disease (CD) with obefazimod, disclosing the enrolment of the first patient. This phase IIb study (NCT06456593) named ENHANCE-CD is a multicentre, double-blind, randomized, placebo-controlled trial, with a design comparable to the com

October 4, 2024 October 4, 2024 1 EN

Bruno Bulic

Bruno Bulic

Abivax positive long-term Ph. II data

Abivax announced excellent interim data on the long-term open-label extension phase of it’s Ph. IIb at a reduced 25mg dose od (versus 50mg od in Ph. IIb). In this extension study, patients who completed the 4-year Ph. IIa or 2-year Ph. IIb with 50mg obefazimod with clinical response could enter thi

October 3, 2024 October 3, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BIC Q3 2024 results preview: a continuation of Q2 trends

On the shelves now: Consumer weekly #42

BIC: a mixed bag of H1 2024 numbers but resilient margin trajectories

On the shelves now: Consumer weekly #42

Abivax: Obefazimod in Crohn's disease clinical development

Abivax positive long-term Ph. II data

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe